Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report
Open Access
- 19 September 2020
- journal article
- case report
- Published by Springer Nature in BMC Nephrology
- Vol. 21 (1) , 1-6
Abstract
Background: We here report on the first observation of a C3 mutation that is related to atypical hemolytic and uremic syndrome (aHUS), which occurred in a pancreatic islet transplant patient. Immunosuppressive treatments, such as calcineurin inhibitors, have been linked to undesirable effects like nephrotoxicity. Case presentation: A 40-year-old man with brittle diabetes, who was included in the TRIMECO trial, became insulin-independent 2 months after pancreatic islet transplantation. About 15 months after islet transplantation, the patient exhibited acute kidney injury due to aHUS. Despite plasma exchange and eculizumab treatment, the patient developed end-stage renal disease. A genetic workup identified a missense variant (p.R592Q) in the C3 gene. In vitro, this C3 variant had defective Factor I proteolytic activity with membrane proteins as cofactor proteins, which was thus classified as pathogenic. About 1 year after the aHUS episode, kidney transplantation was carried out under the protection of the specific anti-C5 monoclonal antibody eculizumab. The patient had normal kidney function, with preserved pancreatic islet function 4 years later. Conclusions: Pancreatic islet transplantation could have triggered this aHUS episode, but this link needs to be clarified. Although prophylactic eculizumab maintains kidney allograft function, its efficacy still needs to be studied in larger populations.Keywords
This publication has 24 references indexed in Scilit:
- Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic SyndromeAmerican Journal of Transplantation, 2013
- Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal TransplantationAmerican Journal of Transplantation, 2012
- KDIGO Clinical Practice Guidelines for Acute Kidney InjuryNephron Clinical Practice, 2012
- Renal Transplantation Under Prophylactic Eculizumab in Atypical Hemolytic Uremic Syndrome With CFH/CFHR1 Hybrid ProteinAmerican Journal of Transplantation, 2012
- A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of functionBlood, 2012
- Thrombotic Microangiopathy After Kidney TransplantationAmerican Journal of Transplantation, 2010
- Eculizumab for Congenital Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2009
- Mutations in complement C3 predispose to development of atypical hemolytic uremic syndromeBlood, 2008
- Complement Mutation-Associated De Novo Thrombotic Microangiopathy Following Kidney TransplantationAmerican Journal of Transplantation, 2008
- Differential Impact of Complement Mutations on Clinical Characteristics in Atypical Hemolytic Uremic SyndromeJournal of the American Society of Nephrology, 2007